About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Antiretroviral therapy does not fully reverse impact of HIV on hepatitis C-related cirrhosis
• High early mortality after starting antiretroviral treatment in Africa
• Nobel prize awarded to French discoverers of HIV
• Fall in number of undiagnosed HIV infections in the US
• Resistance to darunavir related to pre-existing mutations
• Higher levels of drug resistance seen after first-line NNRTI failure than boosted PI failure: meta-analysis
• Wide variation found in anal HPV viral loads in HIV-positive men
• Offering rapid point-of-care tests would increase uptake of HIV testing
• Low rate of spontaneous hepatitis C clearance in patients with HIV; early HIV treatment recommended for those with chronic hepatitis C infection
• Hypersensitivity testing for abacavir slightly more cost-effective than tenofovir use, if both drugs equally potent